COMPREHENSIVE ASSESSMENT OF NEUROLOGICAL DEFICIT AND ITS CORRECTION WITH PIR-10 COMPOUND IN EXPERIMENTAL FOCAL CEREBRAL ISCHEMIA OF RATS

Abstract

Introduction: Correction of motor dysfunction resulting from focal cerebral ischemia is one of the significant problems of pharmacology and experimental therapy. Pyrimidine derivatives in the experiment on rats previously showed cerebroprotective activity, as a result of which it was decided to test the PIR-10 compound for the ability to reduce neurological deficit. Methods: A study was conducted to assess the effect of pyrimidine derivative (PIR-10 50 mg/kg) on neurological deficiency in the conditions of focal cerebral ischemia in rats. The study used mature male Wistar rats weighing 220-240 g (n=40). Focal cerebral ischemia was reproduced by coagulation of the left middle cerebral artery (anesthesia chloralhydrate 350 mg/kg). Neurological deficits were assessed using the McGraw, Combs and D'alecy, Garcia scales. Results: The studied compound PIR-10 contributes to the reduction of neurological deficits in all selected schools in comparison with the control group of animals (McGraw by 68% (p<0,05), Combs and D'alecy by 4,3 times (p<0,05), Garcia by 84% (p<0,05)). In addition, the results obtained after administration of PIR-10 to rats showed a statistically significantly difference from the group of rats receiving a reference drug cavinton. However, complete recovery of motor functions after modeling focal cerebral ischemia was not observed in any group of rats. Conclusion: The PIR10 compound is able to partially correct the neurological deficit that occurs in conditions of cerebral circulatory insufficiency, surpassing the activity of the reference drug cavinton.